With three of the four top neuromodulation companies reporting high-single-digit (HSD) growth in Q123, manufacturers are keeping their fingers crossed that market recovery is well underway. The impact of COVID has lessened significantly and several manufacturers reported that near-term improvement in healthcare staffing levels and post-COVID demand helped drive strong underlying procedure volumes in Q123. Competitors are also seeing gains on new and differentiated product offerings and expanded indications.
It’s too early to say whether or not the market is fully recovered or if the growth in the quarter is due to ...
Read the entire Q123 Neuromodulation Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*
*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.